中国癌症杂志 ›› 2016, Vol. 26 ›› Issue (7): 623-628.doi: 10.19401/j.cnki.1007-3639.2016.07.010

• 论著 • 上一篇    下一篇

定量动态增强磁共振评估乳腺癌新辅助化疗疗效的应用研究

李瑞敏,顾雅佳,彭卫军,毛 健   

  1. 复旦大学附属肿瘤医院放射诊断科,复旦大学上海医学院肿瘤学系,上海 200032
  • 出版日期:2016-07-30 发布日期:2016-08-22
  • 通信作者: 顾雅佳 E-mail:cjr.guyajia@vip.163.com

Role of the dynamic contrast-enhanced MRI in assessing the response to neoadjuvant chemotherapy of breast cancer

LI Ruimin, GU Yajia, PENG Weijun, MAO Jiao   

  1. Department of Radiology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Published:2016-07-30 Online:2016-08-22
  • Contact: GU Yajia E-mail: cjr.guyajia@vip.163.com

摘要: 背景与目的:乳腺癌的新辅助化疗(neoadjuvant chemotherapy, NAC)已成为成熟的治疗方法,但疗效评估尚未有统一有效的方法。该研究即探讨定量动态增强磁共振在乳腺癌NAC疗效评估中的价值。方法:24例术前行NAC的乳腺癌确诊患者(24例均为浸润性导管癌),分别于NAC前、第2个疗程后、化疗结束但术前3个时间点行定量动态增强磁共振检查,分析NAC前后肿瘤最长径及动态增强磁共振定量参数:容量转移常数(Ktrans)、速率常数 (Kep)、血管外细胞外间隙容积比(Ve)的变化。结果:24例患者均为单侧单发乳腺癌病灶,以RECIST标准分为有效组(17个)和无效组(7个),有效组与无效组Ktrans、Kep在NAC前与第2个疗程、化疗前与化疗结束差异均有统计学意义(P<0.05),Ve在有效组与无效组治疗前后差异均无统计学意义(P>0.05)。结论:定量动态增强磁共振可用来评估NAC疗效,并且Ktrans、Kep可做到定量,使评估结果更为客观真实,但Ve对判断治疗效果未见明显优势。

关键词: 乳腺癌, 新辅助化疗, 疗效评估, 磁共振成像, 定量动态增强磁共振检查

Abstract: Background and purpose: Neoadjuvant chemotherapy to breast cancer has become a mature treatment method. The purpose of this study was to evaluate the dynamic contrast-enhanced MRI in assessing the response to neoadjuvant chemotherapy (NAC). Methods: Twenty-four female patients with breast carcinoma (24 were all invasive ductal carcinoma) underwent dynamic contrast-enhanced MRI (DCE-MRI) before, after the second and final cycle of NAC. For each patient and each MRI examination, the maximum diameter of tumor, volume transfer constant (Ktrans), exchange rate constant (Kep), and extravascular extracellular volume fraction (Ve) were compared. According to the method of response evaluation criteria in solid tumor (RECIST), the results of neoadjuvant chemotherapy were divided into responder and non-responder. Results: All 24 patients were unilateral and single breast cancer; there were 17 cases of responders and 7 cases of non-responders according to RECIST criteria. For 17 cases of responders, both the average values of Ktrans and Kep were significantly descended after neoadjuvant chemotherapy (all P<0.05). Conclusion: The quantitative parameters of Ktrans and Kep can evaluate objectively and veridically the response to neoadjuvant chemotherapy for breast cancer in dynamic contrast-enhanced MRI.

Key words: Breast neoplasms, Neoadjuvant chemotherapy, Respanse evaluation, Magnetic resonance imaging, Quantitative dynamic contrast-enhanced MRI